Advanced Code injection

Virica Biotech Graduates from Invest Ottawa Accelerator Program

Invest Ottawa (IO) recently announced its next graduate from the IO Accelerator program, Virica Biotech. The program is designed to use a phased and milestone-based approach to help entrepreneurs grow and scale on their Venture Path. Virica Biotech, a leading innovator in viral enhancement solutions for the biopharmaceutical industry, is the 11th successful graduate from the flagship program.

Virica Biotech is an OBIO® member, an alumnus of our BDSP™ and WiHI programs, and presented at the OBIO® Investment Summit.

Roga Secures $1.7 Million CAD to Reduce Stress and Burnout with its Nerve-Stimulating Website

Toronto and Los Angeles, California-based neurotech start-up, Roga, has set its sights on reducing intense stress and burnout in a convenient, cost-effective, and discreet way.

The mental healthcare-focused company has secured $1.7 million CAD ($1.2 million USD) in pre-seed funding and support from a slew of health tech investors to fuel the launch of its next-generation wearable device, which it plans to roll out this fall.

Roga has presented at the OBIO® Investment Summit.

Noa Therapeutics Receives the Women Entrepreneur Grant at CanWIN 2024

Noa Therapeutics, a preclinical Canadian biotech company aiming to defy the convention of traditional drug development to revolutionize treatment options for those living with complex inflammatory skin diseases, has received the Women Entrepreneur $5,000 grant at the CanWIN 2024 Bridge to Asia Pitch competition.

Noa Therapeutics is an OBIO® member, alumnus of our BDSP™, H2BB™ and WiHI programs, and presented at the OBIO® Investment Summit.

Revolutionizing Stroke Treatment: The Ottawa Hospital First To Adopt Vena Medical’s Innovative Device

July 10, 2024 (Toronto, Ontario) – In a significant advancement in stroke care, The Ottawa Hospital (TOH) has successfully adopted Vena Medical's Balloon Distal Access Catheter (BDAC™) into its stroke treatment protocol. This follows a comprehensive evaluation through OBIO's Early Adopter Health Network (EAHN™), highlighting a leap forward in mechanical thrombectomy effectiveness. 

The Vena BDAC™ combines balloon guide and distal access catheter technologies to significantly improve the First Pass Effect (FPE) in the treatment of acute ischemic stroke (AIS), a life-threatening and debilitating condition. FPE is the successful removal of a blood clot on the first attempt during thrombectomy, which is vital for reducing brain damage. By enhancing this critical factor, the BDAC™ seeks to decrease the debilitating effects and mortality associated with strokes, thereby improving recovery times and overall patient outcomes. This advancement addresses the pressing health and economic challenges of stroke care, offering a promising improvement for those affected by this serious health issue. 

The recent evaluation at TOH indicated significant improvements in stroke treatment outcomes with Vena Medical's BDAC™. FPE increased to 64%, well above the industry average of 44%. These results suggest notable improvements in patient health at the 90-day mark, particularly in terms of functional independence. The adoption of the BDAC™ at TOH highlights its vital role in enhancing stroke care and improving treatment outcomes.

Michael Phillips, Vena Medical’s Co-founder and CEO, remarked, "It's great to see The Ottawa Hospital putting themselves on the map as an early adopter and champion of innovation in Canada. Through EAHN™, TOH is the first in the world to adopt Vena Medical's latest stroke technology, the Vena Balloon Distal Access Catheter as their device of choice. Canadians continue to be the first to benefit from this cost lowering and outcome improving technology developed right in their backyards before it takes the rest of the world by storm." 

“The Ottawa Hospital is always focused on enhancing patient outcomes through innovative solutions,” said Ellen Odai Alie, Director of Medical Imaging at The Ottawa Hospital. “Integrating Vena Medical’s BDAC into our treatment protocol means that more patients can be treated successfully on the first try – marking a significant advancement in stroke care.” 

"OBIO® is pleased to support the adoption of Vena Medical’s latest stroke technology at The Ottawa Hospital through EAHN™,” said Dr. Maura Campbell, President and CEO of OBIO®. "This project exemplifies how EAHN™ can introduce innovative technologies across the healthcare system to improve treatment outcomes and recovery times for serious conditions, including stroke”. 
 
About Vena Medical 

Vena Medical, an ISO 13485 and MDSAP certified company, is creating a suite of tools to change the way physicians perform minimally invasive neurosurgery, starting with the Vena Balloon Distal Access Catheter™, currently available in Canada. The MicroAngioscope™ is the smallest camera in the world, designed for physicians to view inside veins and arteries for stroke treatment. The need for this new product has been evident in stroke treatment through pre-clinical studies published in the American Journal of NeuroRadiology and the Journal of NeuroInterventional Surgery.

For more information on Vena Medical visit www.venamed.ca  
 

About The Ottawa Hospital 

The Ottawa Hospital (TOH) is one of Canada’s top learning and research hospitals where we are guided by our vision to provide the world-class and compassionate care we would all want for our loved ones.   

Our multi-campus hospital, affiliated with the University of Ottawa, is home to the Regional Trauma Centre and Cancer Centre, and to discoveries that are adopted globally.     

Backed by generous support from the community, we are focused on reshaping the future of health care to improve the health of our diverse population of patients from Eastern Ontario, Western Quebec, and Nunavut.     

For more information about The Ottawa Hospital, visit OttawaHospital.on.ca.    
 

About OBIO® 

OBIO®, a not-for-profit, membership-based organization dedicated to advancing health technology innovation and commercialization, is prioritizing the evaluation of new technologies through its Early Adopter Health Network (EAHN™). OBIO® is engaged in strategy, programming, policy development and advocacy to further the commercialization of human health technologies, positioning Canada as a leader in the international marketplace. For more information, please visit OBIO.ca and follow OBIO® on LinkedIn and X


Media contacts: 
Adam Karamath 
Head of Commercial Operations 
Vena Medical 
adam@venamed.ca  

Rebecca Abelson
Media Relations Officer
The Ottawa Hospital
rabelson@toh.ca 

Doriane Rey 
Senior Manager, Marketing & Communications 
OBIO® 
dorianerey@obio.ca 

16 Bit’s Novel AI-based screening tool to address care gap in osteoporosis at Canada’s largest research hospital

July 3, 2024 (Toronto, ON) – In Canada, at least 1 in 3 women and 1 in 5 men will break a bone due to osteoporosis in their lifetime. Bone mineral density (BMD) declines with age, particularly with menopause, and often the first sign of disease is a fracture. Fractures can lead to reduced quality of life, mobility issues, and loss of independence. Despite clinical guidelines, most adults are not screened for fracture risk; in fact, 80% of patients who experience an osteoporotic fracture have never been screened. Annually, the Canadian healthcare system spends a staggering $4 billion dollars on fracture-related costs, which is only expected to rise as the population ages.

Founded by practicing radiologists Dr. Mark Cicero and Dr. Alexander Bilbily in Toronto, 16 Bit Inc. has developed a novel, AI-powered screening tool that analyzes standard X-rays, and alerts the radiologist if the patient is likely to have low BMD. With their medical device software, Rho™, 16 Bit aims to revolutionize osteoporosis detection by triggering the often-overlooked fracture risk assessment.

16 Bit Co-Founder and Co-CEO, Dr. Cicero, explained the concept behind Rho™: “Most adults will have an X-ray at some point, such as a chest X-ray to rule out pneumonia, or a knee X-ray for pain. Rho™ analyzes these X-rays as they are taken, providing insight about a patient’s bone health from images that are being acquired anyway. When Rho™ detects that a patient is likely to have low BMD, the finding is included in the X-ray report, which can remind the physician to consider a fracture risk assessment.”

Through OBIO’s Life Sciences Critical Technologies & Commercialization (LSCTC) Centre of Excellence, 16 Bit and the University Health Network (UHN), Canada’s largest research hospital, are embarking on a study to evaluate Rho™. The evaluation project will build real-world evidence at a multi-site institution that serves a diverse population and gain practical insights from Rho™, which will be critical to scale the tool globally. The evaluation’s outcomes will assess the impact of Rho™ on patient screening, radiology workflow, and costs.

“We are defining a new standard of care for osteoporosis screening. By identifying at-risk patients, earlier than they would have been identified otherwise, and with effective lifestyle modifications and treatment options available, we know we can prevent some of these debilitating fractures,” emphasized Dr. Bilbily.

“We are thrilled to see 16 Bit’s made-in-Ontario AI tool, Rho™, being evaluated at UHN. At OBIO®, we support the seamless integration of ethical AI and other critical technologies into clinical workflows that reduce cost and improve patient outcomes,” said Dr. Maura Campbell, President and CEO of OBIO®. “We have been supporting 16 Bit for many years and are delighted to catalyze their commercialization journey through OBIO’s Life Sciences Critical Technologies & Commercialization (LSCTC) Centre of Excellence”.

About 16 Bit

16 Bit is a Canadian software medical device company focused on discovering unseen opportunities to improve healthcare by leveraging advances in AI. 16 Bit has been a proud beneficiary of Canada’s thriving healthcare technology ecosystem through support from OBIO®, the CAN Health Network, and INOVAIT. For more information, visit www.16bit.ai.

About OBIO®

OBIO®, a not-for-profit, membership-based organization dedicated to advancing health technology innovation and commercialization, is prioritizing the evaluation and implementation of new solutions using critical technologies through its Life Sciences Critical Technologies & Commercialization (LSCTC) Centre of Excellence, supported by the Government of Ontario. OBIO® is engaged in strategy, programming, policy development and advocacy to further the commercialization of human health technologies, positioning Canada as a leader in the international marketplace. For more information, please visit OBIO.ca and follow OBIO® on LinkedIn and X.

Media contacts:

16 Bit
press@16bit.ai

Doriane Rey
Senior Manager, Marketing & Communications
OBIO®
dorianerey@obio.ca

Esprit-ai, Perley Health and OBIO® partner on a ground-breaking project to Support High Quality Dementia Care in long-term care homes

June 27, 2024 (Ottawa, Ontario) – Long-term care homes face urgent challenges in ensuring resident safety and well-being, particularly concerning falls and responsive behaviours, which can include actions such as wandering and aggressive behaviour towards other residents or staff. These behaviours are often seen in residents living with dementia as a way of expressing their needs. Esprit-ai, in collaboration with one of Ontario’s largest long-term care homes, Perley Health, which is part of OBIO’s Early Adopter Health Network (EAHN™), is embarking on an innovative project to address these pressing issues, with funding support from OBIO’s Life Sciences Critical Technology and Commercialization (LSCTC) Centre of Excellence.

As part of the collaboration, the project aims to enable staff to prevent negative resident-to-resident interactions and reduce falls among residents. It also seeks to provide useful clinical insights on sleep patterns and medication use while improving efficiencies in the home.

Esprit-ai is introducing Sense™ Monitoring, a non-invasive technology which offers an innovative approach to enhancing resident safety and care without the need for intrusive devices. This cutting-edge solution, discreetly positioned beneath the resident’s mattress and seamlessly integrated with nurse call systems, harnesses advanced AI algorithms and sensor technology. As a result, Esprit-ai’s solution equips care providers with real-time insights, facilitating proactive intervention and tailored care delivery within long-term care settings.

“We are humbled at the market demand we are seeing for our Esprit-ai Sense™ Monitoring solution and proud to be at the center of this amazing collaboration between OBIO® and Perley Health,” says Patrick Tan, CEO of Esprit-ai.

Dr. Maura Campbell, President and CEO of OBIO®, emphasizes the importance of innovation in addressing pressing healthcare challenges in long-term care settings, “this partnership underscores the significance of leveraging AI technology to improve patient care and optimize resource utilization in long-term care homes. We are delighted to support this project through OBIO’s LSCTC Centre of Excellence.”

“The project’s objectives align with the overarching goal of enhancing the quality of care in long-term care homes while optimizing resource utilization. Through this collaboration, we seek to pioneer innovative solutions that address the complex challenges facing the long-term care sector,” says Akos Hoffer, CEO of Perley Health.

About Esprit-ai:

Esprit-ai™ is a company dedicated to caring. We are passionate about using technology to help seniors live longer, healthier, and safer lives through the continuum of care. Our Esprit-ai Sense™ solution acts as an invisible caregiver, silently observing and protecting your most vulnerable residents. When accidents happen, it promptly and automatically sends messages to the care team for help. Invisible Care™ with no wearables and no cameras.

For more information, visit www.esprit-ai.com.

About Perley Health:

Perley Health is a unique and innovative community that empowers Seniors and Veterans to live life to the fullest. Home to more than 600 Seniors and Veterans in long-term care and in independent apartments, Perley Health provides a number of clinical, therapeutic and recreational services to residents, tenants and people from across the region.  One of the largest and most progressive long-term care homes in Ontario, Perley Health is also a centre for research, education, and clinical innovation. The Perley Health Centre of Excellence in Frailty-Informed Care™ conducts and shares the practical research needed to improve care. Future caregivers come here to study and to acquire hands-on skills and experience.  The Perley Health Foundation is the engine powering our mission to achieve excellence in the health, safety, and well-being of Seniors and Veterans. Every donation empowers us to provide exceptional care while pursuing the research needed to deliver transformative advances.

For more information, visit www.perleyhealth.ca.

About OBIO®:

OBIO®, a not-for-profit, membership-based organization dedicated to advancing health technology innovation and commercialization, is prioritizing the evaluation and implementation of new solutions using critical technologies through its Life Sciences Critical Technologies & Commercialization (LSCTC) Centre of Excellence, supported by the Government of Ontario. OBIO® is engaged in strategy, programming, policy development and advocacy to further the commercialization of human health technologies, positioning Canada as a leader in the international marketplace.

For more information, please visit OBIO.ca and follow OBIO® on LinkedIn and X.

Media contacts:

Jasmine Eh
Esprit-ai
jasmineh@esprit-ai.com

Jay Innes
Director of Communications
Perley Health
jinnes@perleyhealth.ca | (613) 608-3497

Doriane Rey
Senior Manager, Marketing & Communications
OBIO®
dorianerey@obio.ca

Vasomune Therapeutics Receives U.S. FDA Fast Track Designation for AV-001

Vasomune Therapeutics, Inc., recently announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation for AV-001 for the prevention or treatment of moderate-to-severe ARDS in patients hospitalized with viral and/or bacterial respiratory infections. AV-001 is a first-in-class fully synthetic PEGylated peptide targeting the Tie2 receptor which plays a critical role in vascular stability, barrier integrity and endothelial quiescence, particularly within the pulmonary space.

Vasomune Therapeutics is an OBIO® member, an alumnus of our CAAP® program, and presented at the OBIO® Investment Summit.

Oncoustics Awarded INOVAIT Focus Fund to Accelerate AI-Driven Liver Diagnostics at Point of Care

Oncoustics, a Toronto-based medtech startup that develops advanced AI solutions for low-cost, non-invasive surveillance, diagnostics, and treatment monitoring of diseases with high unmet clinical need, has been awarded the INOVAIT Focus Fund to advance its suite of AI-driven tissue characterization solutions. The resulting products may significantly improve patient outcomes and reduce the overall cost of healthcare by providing easier access to screening, diagnostics and monitoring for earlier interventions, as well as improved treatments for all patients with or at risk of asymptomatic structural liver disease.  

Oncoustics is an OBIO® member, alumnus of our BDSP™, CAAP® and EAHN™ programs, and presented at the OBIO® Investment Summit.

Microbix Opens Capacity Expansions

Microbix Biosystems Inc. a life sciences innovator, manufacturer, and exporter, hosted Minister Nina Tangri, Associate Minister of Small Business of Ontario, to celebrate the opening of two expansions to its medical devices manufacturing capacity at one of its three adjacent Mississauga sites.

The Lab was entirely constructed from Ontario-made modular and prefab components. This innovative construction is more cost-effective than conventional framing and enables reconfiguration or relocation. Across its three sites, Microbix now has access to 11 distinct lab areas totaling 17,000 square feet, comprising 50% of its overall space.

Microbix is an OBIO® member and alumnus of our BDSP™ program.

Bayer partners with Luxsonic and OBIO® for enhanced use of Virtual Imaging Platform in clinical trials

June 25, 2024 (Toronto, ON) – Supported by OBIO’s Life Sciences Critical Technologies & Commercialization (LSCTC) Centre of Excellence, Bayer, and its Imaging Core Lab Services team, has partnered with Luxsonic Technologies, Inc. to evaluate and further enhance Luxsonic’s Virtual Imaging Platform (VIP™) as a tool for use in clinical trials. This collaboration between Bayer, Luxsonic and OBIO®, will lead to the development of an enhanced clinical imaging tool for go/no-go decisions, and determination of efficacy, safety, and cost effectiveness of clinical trials.

Bayer’s Imaging Core Lab Services team is a digitally driven, key evidence-generating imaging solution provider for global pharmaceutical and biotechnology companies to facilitate the increasing role of imaging in drug and digital health product development. Luxsonic is dedicated to improving access to radiology services and creating better workflows through the use of augmented reality solutions. Luxsonic’s VIP™ software leverages ethical AI for image analysis and workflow optimization. The LSCTC Centre of Excellence accelerates the health science industry’s use of critical technologies such as ethical AI and fosters the evaluation and adoption of new health technologies across Ontario. This collaboration with Bayer will evaluate and further improve Luxsonic’s virtual reality technology platform to standardize practices, enhance quality, and increase efficiency in the expert radiology clinical trials workflows for diverse assessment criteria.

“Through further enhancement of an intelligent, collaborative, virtual reality-enabled radiology reading platform, Bayer Imaging Core Lab Services, Luxsonic and OBIO’s LSCTC Centre of Excellence aim to reduce product development cycle-time and increase quality and efficiency while reducing costs in clinical trials and Software as Medical Device development,” said Subrata Bose, Head of Bayer’s Imaging Core Lab Services.

“The partnership with Bayer and OBIO’s LSCTC Centre of Excellence represents an important milestone for our company. It’s a great opportunity to expand the use case of our VIP™ software into clinical trials imaging workflow with the goals of standardizing clinical trials practices, improving quality, and efficiency,” said Mike Wesolowski, Founder and CEO of Luxsonic.

“We are thrilled to welcome Bayer as a delivery partner for OBIO’s LSCTC Centre of Excellence to strengthen our shared commitment to advance health tech solutions from early-stage companies in Ontario,” said Dr. Maura Campbell, President and CEO of OBIO®. “This project with Luxsonic is a great example of how ethical AI can be implemented to improve clinical trial workflows and further support wider adoption of the technology in the global market.”

About Bayer

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, “Health for all, Hunger for none,” the company’s products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability, and quality throughout the world. In fiscal 2023, the Group employed around 100,000 people and had sales of 47.6 billion euros. R&D expenses before special items amounted to 5.8 billion euros. For more information, go to bayer.ca.

About Bayer Imaging Core Lab Services

The Imaging Core Lab Services team at Bayer brings end-to-end imaging services to Bayer’s own clinical trials and those of the company’s arm’s length, including scientific consulting, cloud-based image acquisition, quality control, evaluation and management and real-time operational and quality metrics. The team’s network of over 40 core experts, and more than 100 additional internal and external associated physicians and radiologists, is currently involved in over 44 clinical trials and Software as Medical Device developments.

About Luxsonic

Luxsonic is a Canadian medical technology company that develops immersive, interactive, and intelligent software applications for extended reality devices.  Luxsonic’s flagship product, the Virtual Imaging Platform (VIP™) is a digital twin of the radiology reading room that equips physicians with all the tools they need to do their work in virtual reality. Designed for use with portable, all-in-one head mounted displays, Luxsonic VIP™ addresses the global shortage of medical imaging expertise, streamlining workflows and enhancing accessibility. By enabling better workflow, communication and knowledge sharing Luxsonic is working toward a world in which everyone has access to top tier radiology services and expertise. For more information, please visit luxsonic.ca.

About OBIO®

OBIO®, a not-for-profit, membership-based organization dedicated to advancing health technology innovation and commercialization, is prioritizing the evaluation and implementation of new solutions using critical technologies through its Life Sciences Critical Technologies & Commercialization (LSCTC) Centre of Excellence, supported by the Government of Ontario. OBIO® is engaged in strategy, programming, policy development and advocacy to further the commercialization of human health technologies, positioning Canada as a leader in the international marketplace. For more information, please visit OBIO.ca and follow OBIO® on LinkedIn and X.

 

Media contacts:

Luxsonic Technologies Inc.
info@luxsonic.ca

Communications Department
Bayer Inc.
mediacanada@bayer.com

Doriane Rey
Senior Manager, Marketing & Communications
OBIO®
dorianerey@obio.ca

Digital platform shows promising results in providing accessible, scalable healthcare for patients with complex mental disorders

June 13, 2024 (Toronto, ON) – According to data from 2022, over 5 million Canadians (18%) aged 15 and older met the diagnostic criteria for a mood, anxiety, or substance use disorder in the previous 12 months. Of those with a mood, anxiety, or substance use disorder, more than 1 in 3 reported unmet or only partially met mental health care needs.  

A4i, a leading digital platform for supporting people with complex behavioural and mental health conditions, completed a one-year evaluation project with The Royal Ottawa Mental Health Centre (The Royal), one of Canada’s leading mental health care and research centres. With funding support from OBIO’s Early Adopter Health Network (EAHN™), A4i and The Royal worked together exploring the feasibility of integrating the A4i app and clinical portal into clinical practice. The team at A4i along with The Royal’s managers, clinicians and clients supported the implementation of the technology platform within the Ozerdinc Grimes Family Regional Psychosis Clinic. 

“With the right support, people with schizophrenia spectrum illnesses can manage their symptoms and live well. Through this collaboration enabled by OBIO®, we have the potential to expand and strengthen the supports available to our clients using A4i. We are demonstrating how a digital therapeutic mobile app and clinical portal can scale virtual care, care-coordination and create system efficiencies,” said Dr. David Attwood, Clinical Director of the Integrated Schizophrenia Recovery Program at The Royal. 

According to Amos Adler, Co-Founder and CEO of A4i, “We were able to see how A4i creates a safe, anonymous virtual community promoting recovery and proactively identifying risk. We’re thrilled with the outcomes.”  

Through this project, the two respective organizations worked together to integrate the technology into clinical practice, positively impacting the quadruple aim of healthcare, which includes: improving patient experience, reducing cost, advancing population health and improving the provider experience. Based upon the successful outcomes of the project, the A4i product is ready for procurement within EAHN’s member hospitals. 

“We are thrilled to act as the catalyst for innovation and a facilitator for technology partnerships to improve the experience of patients with complex mental health conditions,” said Dr. Maura Campbell, President and CEO of OBIO®. “With the positive outcomes from this study, EAHN™ can spur the successful adoption of this technology in the Canadian mental healthcare market."   

About A4i 

A4i is a platform for supporting people with complex behavioral and mental health conditions. Currently, A4i is being used to target the recovery processes in psychosis and schizophrenia, and newly in opioid use disorders. For more information, please visit a4i.me

The Royal Ottawa Mental Health Centre  

The Royal is one of Canada’s foremost mental health care and academic health centres. Our mandate is simple: to get more people living with mental illness into recovery faster. The Royal combines the delivery of specialized mental health care, advocacy, research and education to transform the lives of people living with complex and treatment resistant mental illness. For more information, please visit theroyal.ca.  

About OBIO® 

OBIO®, a not-for-profit, membership-based organization dedicated to advancing health technology innovation and commercialization, is prioritizing the evaluation of new technologies through their Early Adopter Health Network (EAHN™). OBIO® is engaged in strategy, programming, policy development and advocacy to further the commercialization of human health technologies, positioning Canada as a leader in the international marketplace. For more information, please visit OBIO.ca and follow OBIO® on LinkedIn and X

Media contacts: 

Amos Adler, M.Sc. 
CEO   
A4i 
amos@a4i.me 

Andrea Tomkins 
Writer 
The Royal Ottawa Mental Health Centre 
Andrea.tomkins@theroyal.ca  

Doriane Rey 
Senior Manager, Marketing & Communications 
OBIO® 
dorianerey@obio.ca 

SPEC Labs Secures Lease to Establish State-of-the-Art Wet Lab Facility in Mississauga

SPEC Labs Centre for Advancement of Biomedical Innovation, a leading innovator in scientific research and development, announced that it has secured a lease agreement to construct and operate a shared, multi-tenant wet lab facility in Mississauga, Ontario. This facility marks a significant milestone in advancing collaborative research and fostering innovation within the Ontario scientific community. Mary Argent-Katwala, Senior Director, Stakeholder Engagement at OBIO® attended the announcement event.

The Government of Canada, through the Federal Economic Development Agency for Southern Ontario (FedDev Ontario), is investing $5 million in SPEC Labs to support the not-for-profit corporation’s efforts in creating this new wet lab facility.

Dr. Maura Campbell, CEO and President of OBIO® is on the SPEC Labs Board of Directors and is quoted in this article published in Financial Post.

Acorn Biolabs Secures $11 Million Series A to Boost Access to Regenerative Medicine via Cell Preservation

Toronto-based biotechnology start-up, Acorn Biolabs, which helps customers freeze their stem cells in preparation for cell-based regenerative medicine treatments, has announced approximately $11 million CAD ($8 million USD) in Series A funding across multiple closings. Acorn plans to use this capital to expand its commercial footprint and develop cosmetic offerings.

Acorn Labs is an OBIO® member, alumnus of our BDSP™, CAAP®, H2BB™ and WiHI programs, and presented at the OBIO® Investment Summit.

A.I. Vali Recognized Among Top 10 Healthcare Solutions Providers

A.I.Vali has been recognized among the Top 10 AI Healthcare Solutions Providers A.I. VALI uses proprietary Machine Learning (ML) and Deep Learning (DL) techniques to analyze the data collected from medical images, such as endoscopy video images and tissue biopsies. Their flagship product, AIDREATM (Artificial Intelligence Device for Real-time Endoscopy Analysis) platform, is an innovative, easy plug and play set up, modular AI platform offers clients precise, consistent, and cost-effective solutions for real-time video image analysis, annotation and report creation and upload, starting with endoscopy.

A.I.Vali is an OBIO® member, alumnus of our BDSP™, EAHN™, HealthMINT™ and WiHI programs, and presented at the OBIO® Investment Summit.

Mesosil Secures $2.2 Million to Develop Infection-Fighting Biomaterials for Medical Devices

Toronto-based nanotechnology start-up, Mesosil, has closed $2.2 million CAD in Seed funding to ramp up its production and fuel its commercialization plans. Spun out of the University of Toronto, Mesosil is developing nanometre-scale, silica-based additives designed to prevent infection and disease at the tissue-biomaterial level and extend the lifespan of dental and medical devices like fillers and implants.

Mesosil is an OBIO® member and an alumnus of our BDSP™ and WiHI programs.

Sanofi Opens Advanced Vaccines Facility in Toronto

Sanofi, a global healthcare company, announced the opening of a new state-of-the-art pediatric and adult vaccine manufacturing facility at its Toronto Campus. Building upon its 110-year heritage, as the largest vaccine manufacturing site in Canada, Sanofi's expansion demonstrates the company's commitment to innovation and leadership in global public health. The new facility significantly increases capacity to meet growing Canadian and Global demand for pediatric and adult vaccines for pertussis (whooping cough), diphtheria and tetanus. These vaccines will be exported to 60 markets globally, protecting lives in Canada and around the world.

Gotcare's program evaluation at Women's College Hospital improves healthcare accessibility for homebound older adults

June 11, 2024 (Toronto, ON) — Currently, care for homebound older adults often involves little overlap and continuity between primary care and community care services. Gotcare’s “In The Community (ITC): Health Ambassador” program was developed as an innovative healthcare solution that aimed to provide support at home to older adults through a combination of in-home visits by a health ambassador, health monitoring, virtual care with a nurse, and ongoing interventions addressing social isolation.

With support from OBIO’s Early Adopter Health Network (EAHN™), The Centre for Digital Health Evaluation (CDHE) at Women’s College Hospital (WCH) has successfully completed its evaluation of Gotcare’s ITC program. Findings suggest that 87% of the participants reported that the ITC program helped improve their quality of life once at home. Additionally, 93% of them agreed that the ITC program helped them feel less isolated after returning home.

The evaluation offered a range of services, including routine check-ins or other health monitoring measurements (e.g., blood pressure), support in developing an at home care plan, technology training to use the platform, and access to a virtual nurse via a personalized Gotcare tablet. During visits, the health ambassador documents participants’ well-being. Any health deterioration or symptom exacerbation is flagged by Gotcare’s AI-enabled Community Dashboard, which is monitored by a nurse, and prompts a virtual visit. The nurse then compiles those notes, along with their own interactions with the participants during virtual sessions, and sends them to their family doctor, at a frequency requested and agreed upon by the referring physician or case manager.

“Given the healthcare labour shortage across Canada, it’s more important than ever for everyone to operate at the very tippy top of their scope - including home care providers,” said Chenny Xia, CEO and co-founder of Gotcare. “By upskilling providers to become health ambassadors, and incorporating digital health as a part of care delivery, older adults can receive more timely interventions for low acuity care needs - conveniently, in their own home.”

Of the program participants who completed the survey, approximately 60% indicated that the services provided by the program helped them avoid an unnecessary visit to the emergency department, and approximately 63% of them indicated that the program helped them avoid an unnecessary visit with their family doctor.

Everyone agreed (43%) or strongly agreed (57%) that they were happy with the services provided by the health ambassadors. The majority of program participants were satisfied with the support they received for their at home care plan (79%) and for having their health concerns addressed virtually (93%).

"Our evaluation found that Gotcare's In The Community Program provided great value to their clients,” explained Dr. Jennifer Shuldiner, Scientist at Women’s College Hospital. “They reported that their health ambassador provided emotional support and companionship. They also helped with nutrition, transportation, and groceries. Clients appreciated the consistency of having the same person visit, someone who understood their needs and who they felt comfortable with."

“Nearly all Canadians want to age at home. As people age, it becomes more difficult to make it to their doctor’s office or participate in activities that promote health,” said Dr. Dominik Nowak, Family Physician at Women’s College Hospital. “A health ambassador is simply a flexible prescription for a supportive human — who can help the participant with anything from getting to doctor’s visits, care needs to avoid emergency room visits, all the way to social connection and meaningful activity.”

Following the CDHE’s positive determination of value of the ITC program and a recommendation to proceed with a procurement process, OBIO’s EAHN™ can now provide support to other healthcare organizations interested in the procurement of Gotcare’s ITC program.

“OBIO® is always eager to support the adoption and integration of made-in-Ontario solutions in areas of our healthcare system that have historically been overlooked and have more often than not been neglected,” said Dr. Maura Campbell, President and CEO of OBIO®. “The important work that Gotcare and Women’s College Hospital have carried out to coordinate and integrate primary care with community healthcare services will help revolutionize our approach to aging at home.”

About Gotcare

The health care worker shortage has left many older adults and people living with chronic conditions without access to the care they need. By attracting and upskilling community health workers who have previously left the sector, Gotcare is rehumanizing the patient care journey. They provide personalized in-home care, AI-driven health monitoring, and virtual care support to address low-acuity care needs right at home. Gotcare is a social enterprise and a certified living wage employer. For more information: gotcare.ca.

About Women’s College Hospital

For more than 100 years Women’s College Hospital (WCH) has been developing revolutionary advances in healthcare. Today, WCH is a world leader in health equity and Canada’s leading academic ambulatory hospital. It focuses on delivering innovative solutions that address Canada’s most pressing issues related to population health, patient experience and system costs. The Centre for Digital Health Evaluation at WCH offers timely, high-quality evaluations of digital health technologies at various stages of maturity by partnering with leading experts in the health and technology sectors.

About OBIO®

OBIO®, a not-for-profit, membership-based organization dedicated to advancing health technology innovation and commercialization, is prioritizing the evaluation of new technologies through its Early Adopter Health Network (EAHN™). OBIO® is engaged in strategy, programming, policy development and advocacy to further the commercialization of human health technologies, positioning Canada as a leader in the international marketplace. For more information, please visit OBIO.ca and follow OBIO® on LinkedIn and X.

Media Contacts:

Chenny Xia
CEO
Gotcare
chenny@gotcare.ca

Maria Madden
Manager, Public Affairs
Women’s College Hospital
maria.madden@wchospital.ca

Doriane Rey
Senior Manager, Marketing & Communications
OBIO®
dorianerey@obio.ca   

Satellos Bioscience opens the market

Satellos, a regenerative medicine company dedicated to developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders, went public on the TSX. Frank Gleeson, Co-Founder and Chief Executive Officer, Satellos Bioscience, and his team joined Dani Lipkin, Managing Director, Global Innovation Sector, Toronto Stock Exchange (TSX), to open the market.

Satellos is an alumnus of the CAAP® program and presented at the OBIO® Investment Summit.

KA Imaging’s Reveal Mobi Pro receives Canadian Medical Device Licence from Health Canada

A Canadian Medical Device Licence was issued by Health Canada for Reveal Mobi Pro, KA Imaging Premium Dual-Energy Mobile System. This product is a collaboration with Del Medical, Inc.

The Reveal Mobi Pro integrates KA Imaging’s Reveal™ 35C detector with SpectralDR® technology into a complete mobile X-ray solution. Reveal’s ability to simultaneously acquire conventional and dual-energy images with a single exposure at the bedside improves hospital and patient outcomes, and protects revenue by reducing outflows.

KA Imaging is an OBIO® member, an alumnus of our BDSP™, CAAP®, EAHN™, HealthMINT™ and H2BB™ programs, and presented at the OBIO® Investment Summit.